Adial Pharmaceuticals, Inc. (ADIL) financial statements and ratios from SEC XBRL: revenue $149567.00 (TTM), net margin -5333.5%, revenue growth -16.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $149567.00 |
| Net Margin | -5333.5% |
| Return on Equity | 150.6% |
| Current Ratio | 5.63 |
| Revenue Growth (YoY) | -16.3% |
| EPS Growth (YoY) | 338.6% |
| Price / Sales | 67.10 |
| Altman Z-Score | -18.01 (distress) |
| Sector P/E (Healthcare) | 21.7 |
ADIL overview · ADIL earnings · ADIL KPIs · ADIL investor relations · ADIL ownership · ADIL peers · ADIL filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.